Pricing Log in Create free account

Altimmune, Inc. (ALT) vs Neurogene Inc. (NGNE)

Altimmune, Inc. and Neurogene Inc. are both Biotechnology companies. Altimmune, Inc. and Neurogene Inc. are of similar size ($479.3M and $459.1M). Across the 11 metrics below, Altimmune, Inc. leads on 7 and Neurogene Inc. on 4.

Valuation

Metric ALT NGNE Biotechnology median
P/E n/m n/m 8.50
P/S 8,869.05 n/m 9.71
P/B 0.86 2.42 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2,534.11 n/m 9.21
Earnings yield (35.45%) (21.62%) (33.15%)
Free cash flow yield (18.81%) (16.71%) (25.50%)

Profitability

Metric ALT NGNE Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (28.87%) (45.32%) (56.36%)
Return on assets (25.58%) (41.02%) (48.04%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT NGNE Biotechnology median
Revenue growth (TTM) 130.00% — 6.02%
EPS growth (last fiscal year) 25.37% 0.93% 30.26%
Revenue growth, 5-year CAGR (65.33%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT NGNE Biotechnology median
Debt to equity 0.07 0.00 0.00
Current ratio 26.78 10.64 4.72
Net debt to EBITDA 2.49 2.57 0.96

Dividend

Metric ALT NGNE Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALT NGNE Biotechnology median
Market cap 459.07m 479.27m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack